Format

Send to

Choose Destination
J Oncol Pract. 2018 Jun;14(6):359-366. doi: 10.1200/JOP.18.00204.

Managing Patients With Relapsed Small-Cell Lung Cancer.

Author information

1
City of Hope National Medical Center, Duarte, CA.

Abstract

Despite high response rates to initial therapy, relapses are common in patients with small-cell lung cancer (SCLC). Systemic therapy after first-line failure remains important in the treatment paradigm of SCLC. Reinitiation of a previously administered first-line chemotherapy regimen is recommended for relapse > 6 months from completion of initial therapy. For relapse ≤ 6 months of initial therapy, sequential therapy with single agents is recommended. Clinical trial enrollment should be considered at all stages of treatment of SCLC. This review highlights the available treatment options in relapsed SCLC. In particular, we focus on prospective clinical trials demonstrating activity for the most commonly used agents in this setting. We end with a discussion on future directions and emerging targets with potential to improve outcomes in relapsed SCLC.

PMID:
29894664
PMCID:
PMC6002253
DOI:
10.1200/JOP.18.00204
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center